Poster Abstracts • OFID 2018:5 (Suppl 1) • S467 and was treated 74.6% of the time (Figure 3 ). Significant risk factors for MDR UTI included female gender (P = 0.005), IV abx (P = 0.001), and recurrent UTI (P = 0.017).
invasive infection. In those without concurrent invasive S. aureus infection, male sex (P = 0.033), MRSA (P = 0.008), collection of blood cultures (P = 0.005), and Charlson comorbidity score (P ≤ 0.001) were identified as risk factors for 12-month mortality. Race, inpatient status, specimen type, pyuria, UTI symptoms, and urologic instrumentation were not significantly associated with mortality.
Conclusion. Patients without evident invasive S. aureus infection at the time of urine culture were not observed to present with invasive disease in the following year. Mortality increases with Charlson score and invasive infection in patients with SABU. Clinicians may consider isolated UTI, contamination, and colonization before embarking on extensive searches for occult staphylococcal infection in patients who present without obvious invasive infection, particularly in those without comorbid disease.
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Treatment of Asymptomatic

Background.
Based on large population-based studies, the risk of prosthetic valve endocarditis (PVE) after surgical aortic valve replacement is 0.57% per person year. There is no causal link from asymptomatic bacteriuria (ASB) to PVE; however, antibiotics are often prescribed in an abundance of caution given the catastrophic downside. The risk of PVE is yet to be determined in patients who receive a transcatheter aortic valve replacement (TAVR), but likely lower due to the minimally invasive approach. At our institution, ASB is heterogeneously treated with antibiotics prior to TAVR. Herein we quantified some untoward outcomes of treatment of ASB pre-TAVR.
Methods. A single-center retrospective study was conducted for patients who underwent TAVR between October 2012 and June 2017. Pre-and post-procedural urinalyses (UA), culture results, antibiotic regimens, development of resistance, symptoms of UTI, 30-day readmission rates, and 30-and 90-day mortality rates were collected.
Results. A total of 296 patients with median age of 83 (range 49-97) underwent TAVR. Two hundred and sixty UAs with reflex to culture (137 of which reflexed) and eight additional urine cultures (UC) were sent. One hundred and thrity-three of 145 patients cultured had no documented symptoms. There were 44 patients with positive UC, of which nine (20%) had symptoms. Of the 35 with ASB, 27 received antibiotics prior to TAVR (77%). Among those who were treated, there was one case of C. diff, three cases of development of resistance in an organism previously isolated and three cases of newly acquired MDRO. This amounts to a number needed to harm of 3.86. There were no cases of any of these outcomes, 30-day readmission or death within 90 days for the ASB patients who did not receive treatment. In the treatment group, there was one case of bacteremia for which the causative organism was different from the organism isolated in UC.
Conclusion. In this small cohort of mostly elderly TAVR patients, the rate of ASB was high as expected and most were treated. We documented cases of potential harm associated with antibiotic treatment, and found no such harm episodes in the untreated group. Given the high number needed to harm and the historically low risk of PVE, antimicrobial stewardship experts should continue to encourage avoidance of antibiotics for ASB, including for patients undergoing invasive and minimally invasive cardiac procedures.
Disclosures. All authors: No reported disclosures. Background. Urinary tract infections (UTIs) are among the most common causes for antibiotic prescription. The use of clinical scoring models in predicting infection with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) may help select an adequate empiric treatment.
Utility of Clinical Scoring Models in Predicting Community Acquired Urinary Tract Infections with Extended-Spectrum β-Lactamase-Producing Escherichia coli in a General Hospital in Mexico City
Methods. This retrospective case-control study included all urine cultures with E. coli from symptomatic patients 18 years of age or more admitted to Medica Sur Hospital from December 2014 to 2016. Cases were ESBL producing cultures and controls non-ESBL. Demographic and clinical information was drawn from electronic file. Sensitivities and specificities were performed at various cutoffs and area under the receiver curve (ROC AUC) was determined for each of the two models studied.
Results. A total of 171 cases and 294 controls were included. Table 1 displays the statistically significant variables associated with ESBL in a multivariate regression model. ROC AUC in Figure 1 Background. Urinary tract infections (UTIs) are common in outpatient settings. Evidence-based recommendations suggest empiric treatment of healthy female patients presenting with two or more classic symptoms of UTIs, rather than urine testing. It is unknown how often urine testing is ordered in the community, and if there are opportunities to reduce the number of unnecessary urine tests. This study aims to describe urine testing practices for uncomplicated UTIs in outpatient settings.
Methods. Using the 2009-2013 Truven Health Analytics MarketScan database, we extracted outpatient claims data for premenopausal, nonpregnant women aged 18-44 years who met criteria for an uncomplicated UTI or cystitis with antibiotic prescribed ±5 days of diagnosis. Women with recent infections, hospitalizations, urologic abnormalities, diabetes, chronic kidney disease, immune compromise, or other complicating factors were excluded. Urine laboratory tests coded within ±5 days of index UTI were identified. To explore variation in urine testing practices, we compared frequencies of urine testing types according to patient age, region, provider type, testing location, residence in a metropolitan statistical area (MSA), and office visit using Chi-square tests.
Results. Of 669,892 eligible patients with an uncomplicated UTI, 584,863 (87%) received at least one urine test. Of the patients who received at least one test, 285,639 (49%) patients received both a urinalysis (UA) and culture, 247,740 (42%) received a UA only, and 51,484 (9%) received culture only. Significant variation in testing was observed by patient age, region, provider type, testing location, and office visit (Table 1) . Patients in the Northeast and in urban locations more frequently received both a UA and culture. Patients who received both UA and culture were more likely to have been seen by an OB/GYN, whereas patients treated empirically without testing were more likely to have been seen by emergency physicians.
Conclusion. In contrast to evidence-based recommendations, the vast majority of patients with uncomplicated UTI received at least one urine test. We observed variation in urine testing practices, which suggests that diagnostic testing stewardship opportunities exist for outpatients with UTIs.
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No reported disclosures. Background. Life-threatening syndromic hospital infections including sepsis, ventilator acquired pneumonia, catheter-associated urinary tract infection (CAUTI), and surgical site infections are often caused by multidrug-resistant pathogens. Implementing the targeted narrow-spectrum antimicrobial therapy as rapidly as possible at the onset of infection is critical for lowering morbidity and mortality for these infections. We present the new MultiPath technology for rapid syndromic infection detection, pathogen identification, and phenotypic antimicrobial susceptibility testing (AST). Our feasibility data demonstrate the technology's potential application as a rapid CAUTI diagnostic.
Methods. The MultiPath technology detects and counts cells in a 30-minute assay using nonmagnified digital imaging. For identification, target pathogen cells are labeled using fluorescent in situ hybridization (FISH) with rRNA-specific probes, tagged with magnetic nanoparticles, deposited on a surface, imaged, and quantified. For AST, samples are mixed with growth medium, incubated for 4 hours in the presence of serial dilutions of antibiotics, FISH-labeled, magnetically selected, and quantified by digital imaging. The MultiPath assays use a dye-cushion layer to optically sequester the sample and unbound fluorescent probes from the imaging surface, eliminating the need for sample preparation and wash steps.
